Company
Every investor coverage indicates participated in a round Cann Group raised.
Companies Cann Group acquired or merged with, per published coverage. Buying a company is not investing in one: nothing here counts in the deals column.
| Name | Role | Sources |
|---|---|---|
| Sud Agarwal | Medical Director (former) | SmartCompany |
Stories naming Cann Group. Where several outlets covered the same round, they are bundled under whichever ran the fullest account.
Manufacturing roundup: Amaero appoints Guggenheim to review strategy, Cann completes its Mildura facility, ADN lines up a $4.5m placement, Imugene starts an MSD cancer trial, ABT collects an R&D tax refund.
Roundup of manufacturing briefs: Fable Foods raises seed funding for mushroom-based meat, Nufarm wins US FDA recognition, Alexium commercialises BioCool, Archer patents its quantum chip in Asia, and Cann Group ends its Emyria collaboration.
Manufacturing roundup: AML3D joins a naval shipbuilding research facility with BAE Systems and Flinders University; Cann Group recovers scam losses; Ridley divests its Westbury plant; Skedulo secures $100m from SoftBank's Vision Fund 2.
Medicinal cannabis platform CannVaLate oversubscribed its Series A within a week, collecting $4 million largely from doctor investors, six months after launching, with funds spent on licensing and technology and a Series B planned.